Advanced Filters
noise

Liver Cancer Clinical Trials

A listing of Liver Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 770 clinical trials
J Jinbo Yue, doctor

Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer

Recent years have seen significant advancements in the treatment landscape of advanced hepatocellular carcinoma (HCC), with the emergence of targeted and immunotherapy strategies reshaping first-line therapy. Sorafenib, a multi-targeted tyrosine kinase inhibitor, initially set the standard, followed by approvals for lenvatinib, regorafenib, cabozantinib, and ramucirumab. Immunotherapy, particularly combinations like atezolizumab …

18 - 75 years of age Both Phase N/A
C Camilla Holmgren

Relevance of Sarcopenia in Advanced Liver Disease

Patients with established liver cirrhosis, or end-stage liver disease (ESLD), are at high risk of developing liver cancer (hepatic carcinoma; HCC), portal hypertension, and sarcopenia, all which lead to significant morbidity and mortality. In this patient group the annual incidence of HCC is c. 2-8% and these patients are therefore …

18 - 100 years of age Both Phase N/A
K Kristie Kennedy, MA

Optimizing Y90 Therapy for Radiation Lobectomy

HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic …

18 - 100 years of age Both Phase N/A
S Sanna Norén, MD, PhDstudent

Hemostasis in Liver Cirrhosis and Hepatocellular Cancer

Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.

18 - 100 years of age Both Phase N/A
W WenBo Guo

Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy

. 1 Clarify the difference in efficacy of regofinib combined with TACE compared with second-line treatment of advanced liver cancer; 2. To evaluate the safety and prognostic imaging factors of regorofenib in advanced second-line therapy; 3, to explore whether it is necessary to increase the treatment of TACE in the …

18 - 75 years of age Both Phase N/A
S Shaolin Shen, PhD

Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma

Plasma contains a variety of metabolites, among which sphingolipids, including ceramide, sphingosine, and sphingosine-1-phosphate, serve as important intracellular second messengers and are involved in various cellular signaling pathways, such as apoptosis. We hypothesize that plasma sphingolipid levels may be associated with the efficacy of radiotherapy for liver cancer. This study …

18 - 80 years of age Both Phase N/A

Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning

Developing a deep learning model based on contrast-enhanced ultrasound (CEUS) to predict the prognosis of hepatocellular carcinoma (HCC) and aid choose operation decisions

18 - 100 years of age Both Phase N/A

Role of Photon Counting CT in Detecting Liver Metastatis From Colorectal Cancer

Colorectal cancer is the first leading cause of cancer death in men and second in women. Its incidence rates also increased by 1%-2% annually in young adults (ages <55 years). The liver is the most common site of colorectal cancer metastasis, with approximately 25% 50% of patients developing liver metastases …

18 - 100 years of age Both Phase N/A
J JEAN FREDERIC BLANC, PR

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will …

18 - 100 years of age Both Phase N/A
C Chien-Hung Chen, MD, PhD

A Study of PTX-9908 Injection for Non-resectable HCC With TACE

This is a multicenter, Phase I/II study in patients with non-resectable hepatocellular carcinoma following TACE treatment. Phase I (Open-label dose escalation) This study will be an open-label study with an Accelerated Phase and a Standard Phase. For the Accelerated Phase of the study, one patient per dose level (1 mg/kg, …

20 - 100 years of age Both Phase 1/2

Rewrite in simple language using AI